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reduces tumor volume in a murine xenograft
model of nasopharyngeal carcinoma
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We have previously shown that disruption of promyelocytic leukemia nuclear bodies (PML NBs) is sufficient to
activate the EBV lytic cycle thus making infected cells susceptible to ganciclovir (GCV) mediated killing in vitro. Here
we show that co-administration of GCV and arsenic trioxide (ATO), a PML NB disruptor, reduces tumor volume in a
xenograft model of nasopharyngeal carcinoma utilizing CNE1 cells. When administered at pharmacologic levels, both
GCV and ATO reduced tumor growth while co-treatment with GCV + ATO resulted in a diminution of tumor volume.
Treatment with GCV or ATO individually resulted in an increased number of apoptotic cells while co-treatment with
GCV + ATO synergistically induced apoptosis. Treatment with ATO or co-treatment with GCV + ATO resulted in
expression of EBV lytic proteins. These data suggest that co-treatment with GCV + ATO may provide an effective
treatment for nasopharyngeal carcinoma patients.
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Nasopharyngeal carcinoma (NPC) has a high occurrence
rate in endemic areas of Southern China, Southeast Asia
and North Africa and comprises a substantial health
burden [1-3]. Additionally, a majority of new cases occur
in countries with limited resources for current therapies
or early detection of NPC [4]. Most cases in endemic
areas consist of WHO Type III anaplastic NPC with a
high correlation of Epstein Barr virus (EBV) positivity
while the majority of cases in non-endemic areas consist
of keratinizing squamous cell carcinomas [5-9]. The gen-
etic and geographic pattern to NPC occurrence rates in-
dicates multifocal etiology in that those of Cantonese
descent born in North America display occurrence rates
greater than their geographical counterparts, but less
than that in endemic areas [10-15].
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reproduction in any medium, provided the orwith better clinical outcomes [2,3]. Accordingly, in more
developed areas where early detection and standard
treatments are readily available, mortality rates are de-
clining [16]. In rural areas, initial presentation tends to
be late stage with few treatment options [17]. The delib-
erate induction of EBV lytic reactivation to actuate anti-
viral susceptibility has been proposed as a potential
therapeutic for EBV associated malignancies [18-25]. In-
duction of EBV lytic protein expression, specifically the
virally encoded protein kinase, is essential for activation
of the anti-herpesviral prodrugs [26]. Recently, we have
shown that reactivation of EBV lytic protein expression
by arsenic trioxide (ATO) treatment confers susceptibil-
ity to the antiviral drug ganciclovir (GCV) in vitro [27].
Here we investigated the efficiency of the ATO mediated
reactivation strategy in combination with the antiviral
ganciclovir (GCV) to target EBV positive cancer cells
in vivo in a tumor xenograft model. Treatment with
ATO alone reduced tumor growth consistent with previ-
ous reports [28-30]. Co-treatment with GCV and ATO
(CoTx) demonstrated an advantage over ATO alone, re-
ducing tumor volume to below baseline.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Co-treatment with GCV and ATO reduces tumor volume
in vivo
We have previously reported the ability of ATO treatment
to induce ganciclovir susceptibility in EBV positive NPC
cells in vitro [27]. To investigate whether this treatment
would translate to an in vivo model of NPC, the EBV posi-
tive nasopharyngeal carcinoma cell line, CNE1 < BX1 >
cells were inoculated subcutaneously into NU/NU mice.
Daily intraperitoneal injections of the indicated treatment
were given starting 5 days post inoculation and animals
were sacrificed at day 22 (Figure 1A). Tumors in control
animals displayed an accelerating growth curve over the
21 days while treatment with either GCV or ATO alone
inhibited tumor growth relative to control (Figure 1B).
Co-treatment (CoTx) with GCV plus ATO reduced the
tumor volume to below the baseline (approximately 50%
of original tumor volume, Figure 1C). The difference in
tumor volume in CoTx animals was statistically significant
from all groups. Though the tumor volume difference be-
tween ATO treated and control was statistically signifi-
cant, the tumor volume difference between GCV treated
and either control or ATO was not statistically significant.Figure 1 Co-treatment with GCV + ATO reduces tumor volume in a xe
and treatment regimen. B) Growth curve of the average tumor volume o
investigator and compared to starting volumes as determined by the L*W2
baseline measurement. (*) denotes p < 0.05; (**) denoted p < 0.01; (***) denCNE1 < BX1 > cells display EBER positivity within the
sections
Loss of the EBV genomes in NPC cells passaged in immu-
nodeficient mice has been reported [31]. Chromogenic
in situ hybridization staining for EBER-1 and EBER-2 posi-
tive cells was performed to establish EBV positivity and
to illustrate the morphological differences between the
CNE1 < BX1 > cells and possible infiltration of murine
cells into the tumor (Figure 2). CNE1 < BX1 > cells
displayed EBER positivity in all sections, appear morpho-
logically distinct in size and shape, and were easily distin-
guishable from infiltrating murine cells. In sections from
ATO and CoTx tumors, CNE1 < BX1 > cells appear in
pockets surrounded by murine cells to a greater extent
than in control or GCV treated sections.
Treatment with ATO or co-treatment with GCV + ATO
increases apoptosis
The previously demonstrated increase in apoptosis when
CNE1 < BX1 > cells were treated with GCV +ATO in vitro
[27] together with the observed reduction in tumor vol-
ume measured in the CoTx group for this manuscript sug-
gests that the decrease in tumor volume in vivo occursnograft model of NPC A) Overview of tumor xenograft model
f each treatment group. Tumor volumes were measured by a blind
/2 formula. C) Comparative ending tumor volume as a percentage of
otes p < 0.005.
Figure 2 CNE1 < BX1 > cells within the tumors display EBER positivity and are morphologically distinct from mouse cell infiltrates. In
sections of tumor explants 22 days post injection, EBER-1 and EBER-2 were detected by cytogenic in situ hybridization and stained with NBT/BCIP
(blue). Nuclei were stained with Nuclear Fast Red counterstain (original magnification of 200×).
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change in tumor architecture, tumor sections were fixed
and stained with H & E (Figure 3A). ATO and CoTx sec-
tions showed a reduced cellular density compared with
control or GCV sections. Additionally ATO and CoTx
sections displayed an increased number of apoptotic bod-
ies compared to control. To quantify this increase, cells
displaying apoptotic nuclear morphology were counted in
10 fields from several section samples (Figure 3B). GCV
and ATO treatment sections displayed an increased apop-
totic index (AI) when compared to control, and CoTx
sections displayed an increased AI when compared to con-
trol, GCV or ATO sections.
Active caspase-3 was assessed by immunofluorescence
microscopy and samples were co-stained for expression of
the EBV encoded immediate early lytic protein Zta to fur-
ther quantify the extent of apoptosis (Figure 3C). Expres-
sion of active caspase-3 correlated with nuclei displaying
apoptotic changes in all sections. Sections from ATO and
CoTx samples showed an increase in active caspase-3 as
well as an increase in the number of Zta positive cells. Zta
expression in ATO and CoTx sections displayed a distinct
pattern of pockets of positivity characterized by lower
cellular density and active caspase-3 expression. This pat-
tern was present to a lesser extent in GCV sections.
Treatment with ATO or co-treatment with GCV + ATO
reduces PML NB fluorescent intensity and activates
expression of EBV lytic proteins
ATO has previously been shown to disrupt PML NBs
and increase expression of EBV lytic proteins in EBVpositive NPC cells [27]. To assess whether PML NBs
were affected in vivo by ATO or GCV +ATO treatment,
PML NBs were assessed by immunofluorescence micros-
copy (Figure 4A). In control samples, PML expression
showed distinct punctate nuclear staining. Though PML
NBs were detected in both the ATO or CoTx sections,
the immunofluorescence signal of PML NBs was greatly
reduced when compared to control sections. Treatment
with ATO alone or CoTx resulted in an increase in the
number of cells expressing the EBV immediate early
protein Zta (Figure 3C). To quantify this increase, the
number of Zta positive cells and total CNE1 < BX1 >
cells were counted in 10 random fields from each sample
and the percentage of Zta positive cells was graphed
(Figure 4B). In ATO sections, 14% of cells showed Zta
positivity while 31% of cells in CoTx section were Zta
positive, which correlates with our earlier in vitro find-
ings [27]. Levels of the DNA processivity factor BMRF1,
a Zta responsive early protein, was assessed by quantita-
tive real-time reverse transcriptase PCR (Figure 4C) in
order to affirm the expression of downstream EBV lytic
genes. RNA from the ATO and CoTX tumors showed
increased BMRF1 expression.
Discussion
ATO has been utilized alone and in conjunction with
radiotherapy in both in vitro and in vivo models of NPC
[28-30,32-35]. In studies utilizing tumor xenograft models
of NPC, treatment with ATO alone produced a decrease
in tumor growth compared to controls at doses of 5–10
mg/kg/d. The use of GCV in a previous study utilizing
Figure 3 Co-treatment with GCV + ATO increases apoptosis within tumor sections. A) Representative fields of H&E stained sections from
tumor explants 22 days post injection (original magnification of 200×). B) Total CNE1 < BX1 > nuclei and those displaying apoptotic changes were
counted in 10 random fields from each group comprising multiple sections. C) Tumor xenograft sections from each of the treatment groups
were stained for the immediate early EBV protein Zta (red) and activate Caspase-3 (green). Nuclei were stained with DAPI (blue) (original
magnification of 200X).
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inhibition [36]. Previous work from our laboratory has
shown enhancement of EBV lytic protein expression in
EBV positive NPC cells in vitro through disruption of
PML NBs in response to low dose (give dose) ATO and
increased apoptosis with the addition of GCV [27].
In the current study, treatment with GCV alone
slowed tumor growth (though not statistically signifi-
cant) suggesting a level of spontaneous reactivation inthe CNE1 < BX1 > cell line. This is consistent with the
presence of a low number of Zta positive cells in control
sections and the low number of pockets of Zta positive
cells with a similar pattern of active caspase-3 detection.
Treatment with low dose ATO (1 mg/kg/d) showed growth
inhibition compared to control, consistent with previous re-
ports utilizing higher doses. Importantly, the combination
of GCV and ATO reduced tumor volume compared to
baseline measurements, and histology of these tumors
Figure 4 ATO and CoTx disruption of PML NBs induces EBV lytic protein expression. A) Sections from tumor explants from each of the 4
treatment groups were stained for PML (green). Nuclei were stained with DAPI (blue) (original magnification of 400X). B) Zta positive nuclei and
total CNE1 < BX1 > nuclei were counted in random fields comprising multiple sections from each treatment group (Figure 3C). C) RNA was
isolated from tumor explant tissue samples and levels of the EBV early protein BMRF1 gene product were assessed by reverse transcriptase
real-time PCR.
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of Zta positive and apoptotic cells compared to either con-
trol or single treatment samples. During the course of ex-
periment, no negative effects were observed with any of the
treatments and weight gain was similar among all groups.Recently, Wildman et al. reported stable disease man-
agement and improved quality of life utilizing GCV in
conjunction with valproic acid as a reactivating agent in
3 patients with end-stage NPC, thus supporting a reacti-
vation strategy as a viable treatment in EBV positive
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ine xenograft model and demonstrated that valproic acid
in conjunction with gemcitabine significantly inhibited
tumor growth over the course of treatment [21], but not
a reduction in tumor volume as we report here using a
similar model with GCV +ATO co-treatment. The not-
able differences between the studies preclude a direct
comparison of the results. Notably, lymphoblastoid cell
derived tumors may react differently than NPC cell de-
rived tumors and unlike GCV, gemcitabine induced cell
death is independent of EBV lytic reactivation. The
current report builds on these pioneering studies [21,37]
and provides important evidence that ATO in conjunc-
tion with GCV may be a feasible and effective treatment
for NPC. The utilization of readily available portable in-
fusion therapies that are well tolerated and demonstrate
limited side effects would be especially useful in devel-




CNE1 < BX1 > cells have been previously described and
were cultured in Dulbecco’s Modified Eagle Medium plus
10% fetal bovine serum with 700 ug/ml G418 (Gibco/Life
Technologies, Grand Island, NY) [27]. Animal experi-
ments were performed in accordance with Tulane Univer-
sity Institutional Animal Care and Use Committee
approved protocols and standards. Six to eight week old
outbred NU/NU mice (strain code 088) weighing 18–20
grams were obtained from Charles River Laboratories
(Wilmington, MA) and housed in sterile conditions.
CNE1 < BX1 > cells (7.5×106 cells/mouse) were trypsinized
and mixed with growth factor reduced matrigel (BD
Bioscience, Franklin Lakes, New Jersey) and injected sub-
cutaneously on the right flank of each mouse. Tumor
growth was assessed for 5 days at which time the average
tumor volume was 250 mm3. Animals were randomly
assigned to control (n = 6), GCV (100 mg/kg/d, n = 6),
ATO (1 mg/kg/d, n = 7), or CoTx (100 mg/kg/d GCV +
1 mg/kg/d ATO, n = 7). Working solutions were diluted
such that injection volumes for each group were equal.
Tumor volume was assessed at 3–5 day intervals by a
blinded investigator using the L*W2/2 formula. At 22 days
post injection, mice were euthanized and tumors were
harvested for paraffin sectioning and mRNA isolation.
Isolation of mRNA and quantitative real time reverse tran-
scription PCR detection of BMRF1 mRNA levels was done
as previously described with the following exceptions [27].
At harvest, ½ of the tumor volume was flash frozen in li-
quid nitrogen and stored at −80 deg C. Samples were
homogenized utilizing homogenized utilizing a rotor-
stator homogenizer in RLT Plus buffer. Data is representa-
tive of repeated experiments.Histology and apoptotic Index (AI) analysis
Formalin preserved tumor samples were paraffin imbed-
ded, sectioned on slides and H&E stained by the Histology
Core, Tulane Center for Stem Cell Research and Regen-
erative Medicine. Deparaffinized and rehydrated sections
were bioled 5 minutes in 2xSSC and bathed 10 minutes in
50 mM ammonium chloride prior to blocking and appli-
cation of antibodies. Primary antibodies to Zta (1:100)
(Argene, New York), LMP1 (1:200), PML (1:500) (Santa
Cruz Biotechnology, Santa Cruz, CA), and cleaved
Caspase-3 (1:200) (Cell Signaling, Danvers MA) with sec-
ondary antibodies Alexa Fluor 594 goat anti-mouse
(1:500) and Alexa Fluor 488 goat anti-rabbit (1:500) anti-
bodies (Invitrogen) were used in immunofluorescence de-
tection. An apoptotic index (AI) was assessed from H & E
stained slides. Light microscopy images were taken from
ten random fields with each slide averaging between 200
(CoTx) and 700 (Cntl) CNE1 < BX1 > cells per image. The
AI was calculated as the ratio of cells with apoptotic bod-
ies to the total number of CNE1 < BX1 > nuclei per field.
Chromogenic in situ hybridization (CISH)
Chromogenic in situ hybridization detection of EBV
encoded EBERs was performed by the Molecular Path-
ology Laboratory, Department of Pathology and Labora-
tory Medicine using the ZytoFast © EBV-CISH System.
Briefly, biotin conjugated probes specific to EBER-1 and
EBER-2 were allowed to hybridize followed by complexing
with Streptavidin conjugated alkaline phosphatase. Detec-
tion with nitro blue tetrazolium chloride/5-Bromo-4-
chloro-3-indolyl phosphate (NBT/BCIP) yields a dark
blue stain. Nuclei were stained with Nuclear Fast Red
Counterstain.
Statistical analysis
Multiple comparisons were analyzed by ANOVA with
Modified Bonferroni post hoc test. A p-value <0.05 was
considered significant. For figures, (*) denotes p < 0.05, (**)
denotes p < 0.01, and (***) denotes p < 0.001. Cell counts
are based on 10 random fields from multiple sections for
each condition. Data is represented as the mean (+/−)
SEM.
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